Estimates: Penn National earnings per share were seen dropping 20% to 64 cents, but sales were set to gain 34% to $1.51 billion.
Results: Penn earnings per share declined 44% vs. a year earlier. Revenue came in at $1.51 billion.
2) Further news :
A) PENN ⬇️ more from post-earnings drop, as Business Insider posts article accused Barstool Sports founder Dave Portnoy of sexual misconduct;
B) Penn Rep said it takes matter seriously, still gathering facts. Dave Portnoy responded on Twitter to allegations.
3) In light of (1) & (2), Portnoy’s response to allegations 👇🏾
5) Estimates: It's expected to post an 87-cents-a-share loss for the quarter, a 53% decline year-over-year. Yet sales are seen surging 78% to $236.9 million.
3) “The National Geographic Institute (IGN) has located since last midnight and until 08.00 hours about eleven earthquakes on La Palma. The one of greatest magnitude was the one registered at 01.39 hours this Saturday in #Fuencaliente .”
1) Coronavirus live: England speeds up booster jab rollout, Ukraine reports record daily death toll theguardian.com/world/live/202…
2) 11 patients died Saturday after a fire broke out in a H Covid-19 ward (in the Indian state of Maharashtra). 17 patients were in H ward in the Ahmednagar where the fire started, said Police Inspector Jyoti Karkade. The remaining 6 patients are stable, she added;
3) Austria said on Friday, it was barring those not fully💉 against Covid-19 from cafes, restaurants, & hairdressers as gov’t struggles to convince people to get💉.
~ 64% of 🇦🇹 population is fully💉 against Covid, one of the lowest rates in W Europe, asAustrians are skeptical;
3) Where mods stand.
FT- Rep. Ron Kind says the issue among moderates is whether they’re prepared to vote for the bill, saying it’s “more of a scoring issue right now.” Kind said Pelosi is trying to make sure “people are in a comfortable spot.”
1) Covid live: Germany sets second consecutive daily record for new cases; US vaccine manufacturer loses contract theguardian.com/world/live/202…
2) Pfizer’s antiviral pill for Covid-19 trial stopped early, after drug cut H admission or death risks by 89%, for adults at risk of developing severe disease. Pfizer results surpass trial results of Merck molnupiravir, which halved death or H admission risk for similar patients;
3) German state leaders said on Friday that hospitals could soon soon become swamped by Covid-19 patients and a new lockdown might be needed unless urgent action is taken to reverse a surge in cases;